Nightingale Health Plc’s share capital is EUR 80,000. Nightingale Health has issued 60,928,079 fully paid shares, of which 19,526,438 are Series A shares, 40,296,821 are Series B shares and 1,104,820 are EMP shares, which are employee shares.

Nightingale has three series of shares, which carry different voting rights in the company and different rights to distribution of funds. Series A shares entitle the holder to 10 votes at Nightingale Health’s General Meeting of Shareholders. Series B shares entitle the holder to one vote at the General Meeting of Shareholders. The dividends that will be paid to Series B shares will be five percent higher than those paid to Series A shares and EMP shares. The aforementioned preference only concerns the payment of dividends, no other distribution of assets or capital distribution. EMP shares, which are employee shares, are non-voting shares, and the holder of an EMP share is not entitled to a vote at the general meeting of shareholders. The shares have no nominal value.

The company holds 577,920 EMP shares representing approximately 1 percent of the total number of the company’s shares. Shares held by the company carry no voting rights and no entitlement to dividends.

The shares were entered into the Finnish electronic book-entry securities system maintained by Euroclear Finland on 4 March 2021. The ISIN codes of the share series are

• FI4000490867 (Series A shares),
• FI4000490875 (Series B shares), and
• FI4000490883 (EMP shares).

Trading of the Series B shares on Nasdaq First North Growth Market Finland under the trading code “HEALTH” commenced on 19 March 2021.

Consent, redemption and conversion clauses

Nightingale Health’s Articles of Association include consent, redemption, and conversion clauses with respect to the Series A shares and EMP shares in the company.

More information about the share classes as well as the consent, redemption, and conversion clauses is available in the Articles of Association.